We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Herpes Remains Latent by Producing Self-inhibitory MicroRNA

By Biotechdaily staff writers
Posted on 15 Jul 2008
Molecular virologists have identified the mechanism used by the herpes simplex virus 1 (HSV1) to remain alive but latent in nerve cells until stimulated to renewed activity by excessive sunlight, fever, or other stresses.

During its latent phase, the virus does not replicate and practically the only molecular product that is being made is a type of RNA called latency-associated transcript RNA or LAT RNA. More...
While in the latent state the virus is not susceptible to antiviral treatment.
Writing in the July 2, 2008, online edition of the journal Nature, senior author Dr. Bryan Cullen, professor of molecular genetics and microbiology from Duke University (Durham, NC, USA), said, "It has always been a mystery what this product, LAT RNA, does. Usually viral RNAs exist to make proteins that are of use to the virus, but this LAT RNA is extremely unstable and does not make any proteins.”

Results presented in this study revealed that LAT functioned as a primary microRNA (miRNA) precursor that encoded four distinct miRNAs in HSV-1 infected cells. The investigators showed that one of the miRNAs, miR-H2-3p, was able to reduce expression of ICP0 protein--a viral immediate-early transcriptional activator that is important for productive HSV-1 replication--but did not significantly affect ICP0 messenger RNA levels. When faced with stress, the amount of ICP0 mRNA exceeded the amount of inhibitory miRNA, and the virus was stimulated to begin replication.

"Inactive virus is completely untouchable by any treatment we have. Unless you activate the virus, you cannot kill it,” said Dr. Cullen. "Once the virus is active, a patient would then take acyclovir, a drug that effectively kills replicating HSV1. In principle, you could activate and then kill all the virus in a patient. This would completely cure a person, and you would never get another cold sore.”


Related Links:
Duke University

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.